Additional Supporting Information may be found in the online version of this article.

HEP_22891_sm_SupFig1.tif722KSupplementary Figure S1. Structures of norUDCA, tauro-norUDCA and dinorUDCA. Nor-ursodeoxycholic acid (norUDCA) results from side chain-shortening of ursodeoxycholic acid (UDCA) by one methyl group. Side chain shortening of norUDCA by another methyl group results in dinorursodeoxycholic acid (dinorUDCA). Tauro-norursodeoxycholic acid (T-norUDCA) was obtained by taurine-conjugation of norUDCA.
HEP_22891_sm_SupFig2.tif23240KSupplementary Figure S2. NorUDCA is more effective than tauro-norUDCA and dinorUDCA in reducing sclerosing cholangitis and biliary fibrosis in Mdr2-/- mice. Liver histology (H&E staining) in standard chow-fed (Control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA), and dinorUDCA-fed Mdr2-/- mouse (original magnification 20x). Compared to striking reduction of bile duct injury in norUDCA-treated Mdr2-/- mouse, the effects of tauro-norUDCA are much weaker. DinorUDCA had no influence on large bile duct injury. bd, bile duct; pv, portal vein.
HEP_22891_sm_SupText.doc26KSupplementary Data

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.